CD4+TIL（肿瘤浸润淋巴细胞）在接受 PD-1/PD-L1 抑制剂治疗的非小细胞肺癌患者中的预后意义

CD4+ tumour infiltrating lymphocytes (TILs) have been found to produce a marked effect in anti-tumour immunity. In the present study, the authors explored the predictive value of CD4+ TILs in patients with non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors therapy. The authors searched Cochrane, Embase, PubMed, and the Web of Science with a November 2023 deadline.

This study followed the requirements of the preferred reporting items for systematic reviews and meta-analyses (PRISMA). The data were analysed by Stata MP17. 0 software. Endpoints included objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

In total, 13 studies ultimately met the inclusion criteria. Findings showed high levels of CD4+ TILs in tumour tissue were correlated with better ORR (OR = 1. 78, 95% CI: 1. 15-2. 76, p = 0. 010) in NSCLC patients, rather than PFS (HR = 0. 82, 95% CI: 0. 65-1. 05, p = 0. 11) and OS (HR = 0. 86, 95% CI: 0. 69-1. 09, p = 0. 217).

In addition, high levels of peripheral blood CD4+ T cells correlated with better PFS (HR = 0. 66, 95% CI: 0. 46-0. 94, p = 0. 02), rather than OS (HR = 0. 90, 95% CI: 0. 69-1. 19, p = 0. 461). The results demonstrated that high CD4+ TILs in tumour tissue can predict better ORR for NSCLC patients receiving PD-1/PD-L1 inhibitors, and high peripheral blood CD4+ T cells can predict better PFS. Key Words: CD4-positive T-lymphocytes, Immune checkpoint inhibitors, Non-small cell lung cancer, Peripheral blood, Prognosis, Tumour-infiltrating.